Substrate of CYP 3A4. No data pointing to CYP-inducing properties. One reference: use with care. Occasional observations of non-porphyrinogenicity.

(To be edited, initial data ST OCT 04) Fibric acid derivative used (1200 mg/d) in hyperlipidemia. Longacting. Metabolized by CYP 3A4; inhibitor of CYPs 1A2 (weak), 2C19, 2C8, 2C9. No data point to CYP-induction. Thunell, patient report (n=2): tolerated. South African list: use with care